PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
ProPhase Labs, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Consumer products | $4.35M | $6.77M | $10.14M | $14.32M | $10.48M | $13.24M | $9.88M | 100.0% | -35.8% |
| Diagnostic Services [Member] | $0 | $0 | $24.85M | $108.33M | $68.56M | $1.28M | – | 0.0% | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Consumer Products [Member] | – | – | – | – | – | $13.20M | $9.90M | – | – |
| Diagnostic Services [Member] | – | – | – | – | – | $1.30M | – | – | – |
By region
From the segment and revenue-disaggregation notes of ProPhase Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.